Trifecta Capital Advisors’s Gilead Sciences GILD Stock Holding History

Trifecta Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405K	Buy	3,202 +12	+0.4%	+$1.58K	0.05%	80
2026 Q1	$445K	Buy	3,190 +190	+6%	+$26.6K	0.07%	76
2025 Q4	$368K	Sell	3,000 -60	-2%	-$7.29K	0.05%	81
2025 Q3	$340K	Hold	3,060	–	–	0.05%	81
2025 Q2	$339K	Buy	3,060 +2,707	+767%	+$288K	0.06%	81
2025 Q1	$39.6K	Buy	353 +43	+14%	+$4.44K	0.01%	155
2024 Q4	$28.6K	Hold	310	–	–	0.01%	168
2024 Q3	$26K	Hold	310	–	–	0.01%	176
2024 Q2	$21.3K	Hold	310	–	–	﹤0.01%	185
2024 Q1	$22.7K	Hold	310	–	–	0.01%	171
2023 Q4	$25.1K	Hold	310	–	–	0.01%	165
2023 Q3	$23.2K	Sell	310 -7,087	-96%	-$545K	0.01%	174
2023 Q2	$570K	Sell	7,397 -428	-5%	-$34.1K	0.18%	66
2023 Q1	$649K	Sell	7,825 -220	-3%	-$18.2K	0.23%	64
2022 Q4	$691K	Buy	+8,045	New	+$637K	0.28%	65

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trifecta Capital Advisors's GILD Position: Q2 2026 in Review

Trifecta Capital Advisors increased its Gilead Sciences (GILD) stake by 0.38% in Q2 2026, buying an estimated $1.58K and bringing the position to 3,202 shares worth $405K. The position accounts for 0.05% of the portfolio, ranked #80.

Trifecta Capital Advisors first reported a position in GILD in Q4 2022 and has held it in 15 quarters since. The position peaked at $691K in Q4 2022. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Trifecta Capital Advisors held 3,202 shares of Gilead Sciences worth $405K as of Q2 2026.
Trifecta Capital Advisors bought 12 Gilead Sciences shares in Q2 2026, an estimated $1.58K.
Gilead Sciences made up 0.05% of Trifecta Capital Advisors's portfolio in Q2 2026, its #80 holding.
Trifecta Capital Advisors first reported a position in Gilead Sciences in Q4 2022 and has held it in 15 quarters since.
Trifecta Capital Advisors's Gilead Sciences position peaked at $691K in Q4 2022.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.